Search clinical trials for: JWK002

Total 31 results

West China Hospital

Recruiting

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

X Linked Retinoschisis

China
West China Hospital

Active, not recruiting

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Stargardt Disease 1

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Active, not recruiting

A Pharmacokinetic Study of JS002 in Healthy Subjects

Health Volunteer

China
Allakos Inc.

Terminated

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria (MAVERICK)

Chronic Spontaneous Urticaria

United States, Germany, Poland
Allakos Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Indolent Systemic Mastocytosis

Germany
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
West China Hospital

Recruiting

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Allakos Inc.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Healthy

Australia
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
JW Pharmaceutical

Completed

To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers

Healthy

Korea, Republic of
Allakos Inc.

Completed

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria (CURSIG)

Chronic Urticaria

United States, Germany
Allakos Inc.

Completed

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Eosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Terminated

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (ATLAS)

Atopic Dermatitis

United States, Germany
Allakos Inc.

Completed

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) (ENIGMA 2)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Completed

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Completed

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis (KRONOS)

Vernal Keratoconjunctivitis | Perennial Allergic Conjunctivitis | Atopic Keratoconjunctivitis

United States
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Allakos Inc.

Completed

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis (ENIGMA)

Eosinophilic Gastritis | Eosinophilic Gastroenteritis

United States
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (EoDyssey)

Eosinophilic Gastroenteritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Withdrawn

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA-SC)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis (KRYPTOS)

Eosinophilic Esophagitis

United States, Australia, Netherlands
Allakos Inc.

Completed

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Study Conducted in Healthy Volunteers

United States
JW Pharmaceutical

Completed

To Evaluate the Safety and PK Characteristics in Healthy Volunteers

Healthy

Korea, Republic of
JW Pharmaceutical

Completed

To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers

Healthy

Korea, Republic of
Kiadis Pharma
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Withdrawn

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Randy Trumbower, PT, PhD

Not yet recruiting

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Spinal Cord Injuries | Myelopathy

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China

3

Subscribe